Search / Trial NCT00000146

Optic Neuritis Treatment Trial (ONTT)

Launched by NATIONAL EYE INSTITUTE (NEI) · Sep 23, 1999

Apply for Trial

Trial Information

Current as of March 05, 2024

Unknown status

Keywords

Description

Optic neuritis is an inflammatory disease of the optic nerve that typically affects young adults. Women are affected more often than men. It is second only to glaucoma as the most common acquired optic nerve disorder in persons younger than age 50. In this disorder, closely linked to multiple sclerosis, prognosis for visual recovery is generally good. However, return of visual function is almost never complete. After resolution of optic neuritis, virtually all patients show some signs of optic nerve damage, and most are symptomatic. Even when a patient's acuity recovers to 20/20, abnormali...

Gender

All

Eligibility criteria

  • The major eligibility criteria for enrollment into the ONTT included the following:
  • Age range of 18 to 46 years
  • Acute unilateral optic neuritis with visual symptoms for 8 days or less
  • A relative afferent pupillary defect and a visual field defect in the affected eye
  • No previous episodes of optic neuritis in the affected eye
  • No previous corticosteroid treatment for optic neuritis or multiple sclerosis
  • No systemic disease other than multiple sclerosis that might be the cause of the optic neuritis

Attachments

readout_NCT00000146_2024-03-05.pdf

4.5 MB

NCT00000146_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Little Rock, Arkansas, United States

San Francisco, California, United States

Washington, District Of Columbia, United States

Gainesville, Florida, United States

Chicago, Illinois, United States

Iowa City, Iowa, United States

Baltimore, Maryland, United States

Ann Arbor, Michigan, United States

East Lansing, Michigan, United States

New York, New York, United States

Durham, North Carolina, United States

Portland, Oregon, United States

Philadelphia, Pennsylvania, United States

Houston, Texas, United States

Seattle, Washington, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0